The efforts of the final rule aim to simplify the enrollment process for low-income consumers, provide states with more flexibility in offering routine adult dental services and set guidelines to create access to in-network providers.
The U.S. Department of Health and Human Services (HHS) recently introduced the 2025 Notice of Benefit and Payment Parameters final rule, which pushes the Biden-Harris Administration’s ongoing efforts to expand access to quality, affordable healthcare and elevate guidelines for health insurance marketplace (Marketplace) plans nationwide.
CMS joined the initiative and finalized guidelines for issuers and Marketplaces, as well as requirements for various entities assisting Marketplace consumers, affecting programs such as Medicaid, CHIP, and BHP policies, according to CMS.
The efforts of the final rule aim to simplify the enrollment process for low-income consumers, provide states with more flexibility in offering routine adult dental services and set guidelines to create access to in-network providers, per an HHS press release.
In the release, HHS Secretary Xavier Becerra shared that more than 21 million Americans signed up for high-quality, affordable healthcare coverage through the Affordable Care Act Marketplaces in 2024.
“This rule will allow coverage of routine dental benefits for the first time, expand requirements to ensure reliable access to health care providers, and ensure consumers with lower incomes can sign up for coverage when they need it,” Becerra said.
Below are the key advancements of the final rule, per HHS:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More